Moolec Science (MLEC) and Its Competitors Head to Head Review

Moolec Science (NASDAQ:MLEC) is one of 493 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Moolec Science to related companies based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Profitability

This table compares Moolec Science and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,194.89%	-103.05%	-26.50%

Institutional & Insider Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 32.8% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 20.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Moolec Science has a beta of -0.54, meaning that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s competitors have a beta of 1.22, meaning that their average stock price is 22% more volatile than the S&P 500.

Earnings & Valuation

This table compares Moolec Science and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.50
Moolec Science Competitors	$1.60 billion	$49.77 million	112.30

Moolec Science’s competitors have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Moolec Science and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	966	2819	6942	111	2.57

Moolec Science presently has a consensus price target of $6.00, indicating a potential upside of 567.41%. As a group, “Biotechnology” companies have a potential upside of 25.26%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Moolec Science is more favorable than its competitors.

Summary

Moolec Science competitors beat Moolec Science on 8 of the 13 factors compared.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.